Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine preparation for treating severe myasthenia

A technology for myasthenia gravis and pharmaceutical preparations, applied in the field of medicine, can solve the problems of death, can not prevent the development of MG disease, etc., and achieve the effects of good curative effect, safe toxic and side effects, and quick effect.

Inactive Publication Date: 2009-12-23
张国新
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above-mentioned medicines and treatment methods can only relieve the symptoms temporarily, but cannot prevent the development of the MG disease. The patients with MG tend to get more and more serious, and eventually die if they cannot be cured.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment one: the preparation of injection

[0022] A pharmaceutical preparation for treating myasthenia gravis according to the present invention comprises medicinal sodium thiosulfate with an effective therapeutic dose and pharmaceutically acceptable pharmaceutical auxiliary materials.

[0023] The pharmaceutical preparation described in this embodiment is an injection for acupoint injection, and every 100 milliliters of the injection contains 5.1-7.7 grams of medicinal sodium thiosulfate. Sodium chloride is selected as a pharmaceutical auxiliary material, and the said 100 milliliter injection contains 8.5-9.0 grams of medicinal sodium chloride.

[0024] The preparation method includes two methods: (1) 8.5-9.0 grams of medicinal sodium chloride and the dosage of medicinal sodium thiosulfate are dissolved in 100 milliliters of water for injection; (2) the dosage of medicinal sodium thiosulfate Sodium sulfate was dissolved in 100 ml of 0.85-0.90% normal saline.

[0...

Embodiment 2

[0027] Embodiment two: the preparation of powder injection

[0028] A pharmaceutical preparation for treating myasthenia gravis according to the present invention comprises medicinal sodium thiosulfate with an effective therapeutic dose and pharmaceutically acceptable pharmaceutical auxiliary materials.

[0029] The pharmaceutical preparation for treating myasthenia gravis according to the present invention, the pharmaceutical preparation is powder injection for acupoint injection, the weight percentage of its components is: medicinal sodium thiosulfate 1-100%, medicinal excipients 0-99% %.

[0030] The powder injection is sterile powder injection or sterile freeze-dried powder injection.

[0031] The preparation method adopted in this example is conventional powder injection or freeze-dried powder injection method. Usually, add water for injection according to 10 times of the weight of medicinal sodium thiosulfate, vacuum dry or lyophilize after subpackaging to obtain the f...

Embodiment 3

[0033] Embodiment three: clinical curative effect

[0034] The inventor has practiced medicine in the myasthenia gravis specialist of the hospital for decades, according to the clinical manifestation type of myasthenia gravis (MG), detailed analysis is as follows:

[0035] (1) Ocular muscle type MG: mainly ptosis, diplopia, strabismus, very few MG patients do not ptosis, palpebral fissure cannot close, this is the performance of the seventh pair of cranial nerves. The eyes of some patients are fixed in the middle position and cannot move in any direction. At the same time, it can be seen that the skin also has pathological changes before or after: the skin gradually hardens, lacks elasticity, rough epidermis, pigmentation, hypoesthesia, skin striations appear on the large joints of the upper and lower limbs and the waist, similar to women's stretch marks, and the skin on the joints of the upper and lower limbs The lines run vertically, and the lines on the waist line run hori...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines and relates to a medicine preparation for treating myasthenia gravis. The pharmaceutical preparation of the present invention comprises medicinal sodium thiosulfate of effective therapeutic dose, and pharmaceutically acceptable pharmaceutical auxiliary materials. The pharmaceutical preparation is injection solution or powder injection for acupoint injection. The pharmaceutical preparation of the present invention can cure patients with myasthenia gravis under the guidance of the treatment concept of integrated traditional Chinese and western medicine, and has quick effect, good curative effect, safety, short course of treatment, no recurrence after healing, and is easy to produce industrially, and is suitable for clinical application .

Description

technical field [0001] The invention belongs to the field of medicines and relates to a medicine preparation for treating myasthenia gravis. Background technique [0002] Myasthenia gravis (MG) is a disease manifested by muscle weakness, mainly manifested by weakness and fatigue of skeletal muscles. Myasthenia gravis does not show the weakness of the muscles of the whole body as soon as the disease occurs. The disease is often caused by the involvement of one or more groups of muscles and the weakness of the corresponding muscles first appears. Different parts of the muscles involved may have different manifestations. [0003] The incidence rate of myasthenia gravis (MG) in the natural population is 1:5000. According to the analysis of relevant data, the incidence of this disease has a tendency to increase in the past ten years. The disease can occur at any age, and there are data showing that the age of onset has two peaks: one is under the age of 10, accounting for about ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K33/04A61K47/02A61K47/16A61K47/26A61K9/08A61K9/14A61K9/19A61P21/04
Inventor 张国新
Owner 张国新
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com